Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 24 studies | 45% ± 20% | |
glutamatergic neuron | 13 studies | 58% ± 23% | |
oligodendrocyte precursor cell | 13 studies | 36% ± 16% | |
smooth muscle cell | 10 studies | 25% ± 7% | |
GABAergic neuron | 10 studies | 44% ± 20% | |
neuron | 6 studies | 33% ± 9% | |
interneuron | 6 studies | 41% ± 19% | |
astrocyte | 5 studies | 29% ± 21% | |
amacrine cell | 5 studies | 38% ± 19% | |
Mueller cell | 5 studies | 23% ± 9% | |
fibroblast | 5 studies | 29% ± 12% | |
endothelial cell | 4 studies | 44% ± 16% | |
granule cell | 4 studies | 36% ± 18% | |
retina horizontal cell | 4 studies | 23% ± 8% | |
GABAergic interneuron | 3 studies | 49% ± 15% | |
retinal ganglion cell | 3 studies | 27% ± 2% | |
GABAergic amacrine cell | 3 studies | 33% ± 6% | |
glycinergic amacrine cell | 3 studies | 47% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 16 studies | 36% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 1885.18 | 2623 / 2642 | 99% | 10.34 | 699 / 705 |
pancreas | 98% | 895.79 | 320 / 328 | 81% | 2.48 | 145 / 178 |
breast | 99% | 1489.41 | 456 / 459 | 76% | 3.67 | 852 / 1118 |
prostate | 91% | 955.52 | 224 / 245 | 75% | 2.35 | 375 / 502 |
adrenal gland | 93% | 775.29 | 240 / 258 | 72% | 2.89 | 165 / 230 |
lung | 100% | 3219.76 | 578 / 578 | 63% | 1.95 | 731 / 1155 |
thymus | 99% | 765.91 | 645 / 653 | 53% | 1.16 | 318 / 605 |
kidney | 79% | 729.91 | 70 / 89 | 73% | 4.45 | 654 / 901 |
uterus | 100% | 5679.42 | 170 / 170 | 36% | 1.76 | 166 / 459 |
esophagus | 64% | 460.92 | 919 / 1445 | 63% | 1.72 | 116 / 183 |
ovary | 78% | 763.73 | 140 / 180 | 47% | 1.80 | 204 / 430 |
bladder | 76% | 415.86 | 16 / 21 | 29% | 0.70 | 147 / 504 |
adipose | 100% | 2212.05 | 1202 / 1204 | 0% | 0 | 0 / 0 |
muscle | 98% | 796.49 | 784 / 803 | 0% | 0 | 0 / 0 |
spleen | 98% | 1400.67 | 235 / 241 | 0% | 0 | 0 / 0 |
heart | 83% | 788.70 | 718 / 861 | 0% | 0 | 0 / 0 |
skin | 46% | 333.51 | 835 / 1809 | 34% | 1.08 | 159 / 472 |
intestine | 57% | 338.66 | 554 / 966 | 22% | 0.63 | 115 / 527 |
blood vessel | 75% | 874.49 | 995 / 1335 | 0% | 0 | 0 / 0 |
stomach | 27% | 133.60 | 96 / 359 | 37% | 1.05 | 105 / 286 |
liver | 30% | 132.76 | 68 / 226 | 26% | 0.53 | 105 / 406 |
tonsil | 0% | 0 | 0 / 0 | 38% | 0.80 | 17 / 45 |
eye | 0% | 0 | 0 / 0 | 3% | 0.03 | 2 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_0019934 | Biological process | cGMP-mediated signaling |
GO_0006182 | Biological process | cGMP biosynthetic process |
GO_0007263 | Biological process | nitric oxide mediated signal transduction |
GO_0070482 | Biological process | response to oxygen levels |
GO_0010750 | Biological process | positive regulation of nitric oxide mediated signal transduction |
GO_0005829 | Cellular component | cytosol |
GO_0008074 | Cellular component | guanylate cyclase complex, soluble |
GO_0005525 | Molecular function | GTP binding |
GO_0020037 | Molecular function | heme binding |
GO_0005515 | Molecular function | protein binding |
GO_0004383 | Molecular function | guanylate cyclase activity |
Gene name | GUCY1A2 |
Protein name | Guanylate cyclase soluble subunit alpha-2 (GCS-alpha-2) (EC 4.6.1.2) |
Synonyms | GUC1A2 GUCSA2 |
Description | FUNCTION: Has guanylyl cyclase on binding to the beta-1 subunit.; FUNCTION: Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits. |
Accessions | P33402 ENST00000282249.6 [P33402-2] ENST00000347596.2 [P33402-3] ENST00000526355.7 [P33402-1] |